Loading data for NSRX — first visit, this takes a few seconds.
Nasus Pharma Ltd. (NSRX)
NYSE American: NSRX
· Real-Time Price · USD
3.73
-0.02 (-0.53%)
At close: Sep 04, 2026, 3:06 PM
3.73
+0.00%
After-hours: 7:48 PM
The price, the headline numbers and the latest news, in one place.
Nasus Pharma Ltd. (NSRX) Stock Price, Analysis & Data
-0.40% (1D)
| Bid | 3.33 |
| Market Cap | 43.8M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.6M |
| 0.00 | |
| -1.13 | |
| n/a | |
| n/a | |
| P/B (ttm) | 3.98 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 4 |
| Volume | 829 |
| Avg. Volume (20D) | 18,219 |
| Open | 3.53 |
| Previous Close | 3.75 |
| Day's Range | 3.53 - 3.73 |
| 52-Week Range | 1.98 - 9.50 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NSRX
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for th...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Aug 13, 2025
Employees 7
Stock Exchange NYSE American
Ticker Symbol NSRX
Website https://www.nasuspharma.com
Financial Performance
In 2025, Nasus Pharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -5.86M, an increase of 282.25%.
Financial StatementsEarnings Surprise
Nasus Pharma has released their quarterly earnings on Aug 17, 2026:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of -0.54 misses estimates by -0.31, with -Infinity% YoY decline.